Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rheumatoid Arthritis
Intervention: Infliximab Increased Frequency (Drug); Infliximab Increased Dose (Drug); Infliximab Control (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Merck Sharp & Dohme Corp.
Summary
This Phase IIIb, randomized, multi-national, multi-center, blinded study of Infliximab (IFX)
in subjects aged 18 and older with active RA is being conducted to assess whether increasing
either the infusion dose or infusion frequency in patients presenting with a disease flare
after an initial response to infliximab results in a significant improvement in disease
activity.
Subjects responding to an initial infliximab treatment regimen, who flare during
continuation of treatment at 3 mg/kg administered every 8 weeks, will be randomly assigned
to one of 3 different dosing regimens of infliximab and will be treated for 4 or 5
consecutive infusions for a total duration of 24 weeks. The infliximab control group and the
infliximab increased dose group are evaluator and subject-blinded. The increased frequency
group is not blinded. Clinical assessments of disease activity will be based the European
League Against Rheumatism (EULAR) criteria for response. Safety parameters will be assessed
at every infusion.
A disease flare is defined by an increase in DAS28 with 0. 6 or more at screening, when
compared to the DAS28 score measured immediately prior to the last Remicade® infusion and
depends upon the actual score as well. Since prior to enrollment, the subject received
Remicade® as per routine clinical practice, the days on which infusions were administered
and assessments are done during the induction period do not have to be exactly at Week 2, 6
and 14.
- Drug: Infliximab Control (double-blinded)
- Drug: Infliximab Increased Dose (double-blinded)
- Drug: Infliximab Increased Frequency (open-label)
Clinical Details
Official title: Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change in Disease Activity Score Based on 28 Joint Count (DAS28) Score.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- aged 18 years or more
- with RA according to ACR criteria
- presented with a disease flare after initial response to infliximab, with both
response and flare being defined using the DAS28 score (EULAR criteria)
- received the standard Remicade® dosing schedule per the EU label (3 mg/kg at Weeks 0,
2, 6, [and 14])
- an initial response documented by moderate or good DAS28 improvement (EULAR criteria)
from Week 0 to Week 6 or 14.
Exclusion Criteria:
- a female who is, or intends to become, pregnant during or within 6 months of the end
of the study, is nursing or not using adequate contraceptive measures
- has not observed the designated periods for concomitant medications
- used any investigational medical product within 30 days prior to Baseline
- any clinically significant deviation from normal in the physical examination or chest
X-ray that in the investigator's judgment, may interfere with the study evaluation or
affect subject safety
- rheumatic disease other than RA or has any systemic inflammatory condition with signs
and symptoms that might confound the evaluations of safety and toxicity
- allergic reaction/sensitivity to the study drug or its excipients that requires
corticosteroid pre-infusion medication.
Locations and Contacts
Additional Information
Starting date: March 2006
Last updated: April 7, 2015
|